Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri… - Blood, The Journal …, 2011 - ashpublications.org
The median age of chronic myeloid leukemia (CML) patients is∼ 60 years, and age is still
considered an important prognostic factor, included in Sokal and EURO risk scores …
considered an important prognostic factor, included in Sokal and EURO risk scores …
[引用][C] A new standard treatment for chronic myelogenous leukemia.
M Kalaycio - Current Hematology Reports, 2004 - europepmc.org
A new standard treatment for chronic myelogenous leukemia. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us …
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us …
[HTML][HTML] Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Background Chronic myeloid leukemia is successfully managed by imatinib therapy, but the
question remains whether treatment must be administered indefinitely. Imatinib …
question remains whether treatment must be administered indefinitely. Imatinib …
The argument for using imatinib in CML
S Claudiani, JF Apperley - Hematology 2014, the American …, 2018 - ashpublications.org
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.
F Demirkan, OGG Sevindik, A Karaman, I Alacacioglu… - 2015 - ascopubs.org
e18024 Background: Tyrosine kinase inhibitors are the mainstay of treatment of chronic
myeloid leukemia (CML). Recently, four different generic Imatinib formulations were …
myeloid leukemia (CML). Recently, four different generic Imatinib formulations were …
Imatinib mesylate for the treatment of chronic myeloid leukemia
S Soverini, G Martinelli, I Iacobucci… - Expert review of …, 2008 - Taylor & Francis
Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of
targeted therapy has come true. CML is invariably associated with a specific genetic lesion …
targeted therapy has come true. CML is invariably associated with a specific genetic lesion …
Curing CML with imatinib—a dream come true?
M Deininger - Nature Reviews Clinical Oncology, 2011 - nature.com
Imatinib was discontinued in patients with chronic myeloid leukemia (CML) who gained a
complete molecular response (CMR). Of those patients with at least 12 months follow-up …
complete molecular response (CMR). Of those patients with at least 12 months follow-up …
Chronic myeloid leukemia in the imatinib era
BJ Druker - Seminars in hematology, 2003 - Elsevier
The results of imatinib (Gleevec)(formerly STI571) therapy for chronic myeloid leukemia
(CML) have continued to improve and have surpassed almost everyone's predictions …
(CML) have continued to improve and have surpassed almost everyone's predictions …
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS …
BJ Druker, F Guilhot, S O'Brien… - Journal of Clinical …, 2006 - ascopubs.org
6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
HM Kantarjian, M Talpaz, S O'Brien… - Blood, The Journal …, 2003 - ashpublications.org
We investigated whether increasing the dose of imatinib mesylate might overcome drug
resistance in patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous …
resistance in patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous …